DRG Epidemiology’s coverage of sarcoidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of sarcoidosis for each country, as well as annualized case counts projected to the national population. The patient populations are forecast over a period of 20 years.
DRG Epidemiology’s sarcoidosis forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of sarcoidosis over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following sarcoidosis subpopulations:
- Diagnosed incident cases.
- Diagnosed lifetime prevalent cases.
- Diagnosed current prevalent cases.
- Organ involvement in sarcoidosis.
Note: Coverage may vary by country.
- Sarcoidosis - Epidemiology - Mature Markets Data
- Key Findings
- Incidence of Sarcoidosis per 100,000 per Year Among People Aged 20+ in 2018 and 2038
- Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Sarcoidosis over the Next 20 Years
- Key Findings
- Epidemiology Data
- Diagnosed Incidence
- Diagnosed Lifetime Prevalence
- Diagnosed Current Prevalence
- Organ Involvement in Sarcoidosis
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Sarcoidosis
- Studies Excluded from the Analysis of Sarcoidosis
- Risk/Protective Factors
- Risk/Protective Factors for Sarcoidosis
- Literature Review
Author(s): Johnson Olabisi, MBBS, MSc; Nishant Kumar, MPH
Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space.
Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.